Ensoma acquires Danish CRISPR university spin-off
![Stefano Stella, founder at Chief Technology Officer of Twelve Bio | Photo: Twelve Bio / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/14802678/2y4vss/ALTERNATES/schema-16_9/doc7odcqhpkjk8hypuxb4y.jpg)
Twelve Bio, which has for its short three-year existence been focused on improving the gene-editing CRISPR technology, has been acquired by US-based Ensoma, a developer of genomic medicines within immuno-oncology, a joint company press release announces.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Snipr Biome chose clinical debut in CRISPR-ready USA
For subscribers